" /> Autologous TGFbRII-knockout Anti-interleukin-13 Receptor Alpha 2 CAR T-cells - CISMeF





Preferred Label : Autologous TGFbRII-knockout Anti-interleukin-13 Receptor Alpha 2 CAR T-cells;

NCIt synonyms : Autologous TGF-betaR2KO/IL13R-alpha2-CAR T Cells; Autologous TGFbRII-KO Anti-IL13Ra2 CAR T-cells; Autologous TGFbRII-KO Anti-IL13Ra2 CAR-T Cells;

NCIt definition : A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for interleukin-13 receptor alpha 2 (IL13Ra2), and to knock out the expression of transforming growth factor-beta receptor II (TGFbRII), with potential immunostimulating and antineoplastic activities. Upon administration, autologous TGFbRII-KO anti-IL13Ra2 CAR T-cells target and bind to IL13Ra2 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing IL13Ra2. IL13Ra2, a cancer-associated receptor, is overexpressed by a variety of tumor cell types including glioblastoma multiforme (GBM); it is associated with increased invasiveness of tumor cells. By knocking out the expression of TGFbRII, the immunosuppressive cytokine TGF-beta is unable to bind to the T-cells and prevent the activation of the T-cells. TGF-beta contributes to the immunosuppressive nature of the tumor microenvironment (TME), and plays a key role in promoting tumor initiation, metastasis, and suppressing anti-tumor immunity.;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
30/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.